We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Screening Strategies Used in Drug Discovery
Article

Screening Strategies Used in Drug Discovery

Screening Strategies Used in Drug Discovery
Article

Screening Strategies Used in Drug Discovery

Read time:
 

Want a FREE PDF version of This Article?

Complete the form below and we will email you a PDF version of "Screening Strategies Used in Drug Discovery "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Though rewarding, the process of drug discovery is a complicated journey filled with uncertainties. The process begins with the identification of a disease or a therapeutic area with an unmet need. Once a “druggable” target is found, the process of drug screening starts. In drug screening, molecules that can interact with the target and/or facilitate the desired phenotypic response are identified. 

Advances in combinatorial chemistry and molecular biology have facilitated the identification of an increased number of molecular targets and this has demanded the development of novel screening approaches. 

This article highlights some of the different screening strategies used during drug discovery. Key advances and challenges associated with the techniques are also discussed.

High-throughput screening in drug discovery


High-throughput screening (HTS) is a process used routinely in early-stage drug discovery. HTS is used to detect “hit” molecules with activity against a target of interest, from large compound libraries that can comprise thousands of molecules. Once identified, these hit molecules are validated and refined to produce lead compounds with improved selectivity and potency which can be further tested to identify a potential drug candidate for preclinical testing. HTS involves the use of robotics, liquid/ microplate handling systems and microplate readers to detect, track and quantify the events. It also requires specialized software for instrumentation control and data processing.

Though a key tool, assessing drug properties such as toxicity and bioavailability may be a challenge with HTS. HTS is basically used to assist lead optimization – it may be seen as a
fast scan of biological entities in which candidates with poor or negligible effect can be quickly excluded.

How To Find Promising Small Molecule Leads

Learn how scientists in the drug discovery field search for the most promising lead compounds. Dr. Claire Hatty from NanoTemper will highlight case studies demonstrating the value of biophysical tools in drug discovery workflows. In the second half of the webinar, Dr. Jana Wolf from Domainex Ltd will explain how they apply these tools for their drug discovery projects. Watch this webinar to discover how one multifunctional set of tools can be exploited at various stages of early drug discovery and help to address key challenges.

Watch Webinar

High-content screening – Taking high-throughput screening to the next level


High-content screening (HCS), a technique originally developed to complement HTS, has gained immense popularity in recent years. HCS integrates the efficiency of high-throughput techniques with cellular imaging to collect quantitative data from complex biological systems. 

 “High-throughput assays using multititre plates and automated fluorescence microscopy converged in the 1990s when the term "high-content screening" was coined to emphasize the complex subcellular morphological and intensity-based readouts that allow studying variations in a cell population compared to a single population-averaged readout per perturbation,” explains
Janos Kriston-Vizi, group leader of the Bioinformatics Image Core (BIONIC) at the Laboratory for Molecular Cell Biology (LMCB), University College London.

With HCS, multiple properties of individual cells or organisms can be
studied at once. Automated microscopy, image processing and visualization tools are used in combination to extract data from cell populations. HCS typically involves fluorescence imaging of samples in a high-throughput format and provides quantitative reports on various specifics such as the spatial distribution of targets and individual cell and organelle morphology. 

Kriston-Vizi says, “High-content screening improves the throughput in preclinical drug discovery. Screening small molecule, natural product, genetic or approved drug libraries using a monolayer cell culture format allows you to test thousands of perturbations in a single experiment while preserving physiological relevance compared to biochemical assays.” 

Most HCS is currently carried out using conventional or two-dimensional (2D) tissue culture. However,
3D cell culture models are also being explored. By increasing physiological relevance, 3D models are set to transform the HCS arena. “3D high-content screening with spheroids and organoids increases the physiological relevance and aims to reduce the high attrition rate in drug discovery”, notes Kriston-Vizi.

Fragment-based drug discovery – The bottom-up approach


Fragment-based drug discovery (FBDD) is another well-known strategy used for drug discovery. In contrast to HTS campaigns, whereby huge libraries of complex compounds are screened, FBDD uses smaller libraries containing hundreds of low-complexity compounds or “fragments”. Compared to HTS, FBDD requires lower research investments. 

By using fragments, the complexity of the compounds being screened is reduced, allowing for more of the target’s binding site to be investigated (Figure 1). FBDD also acts as a great starting point to design lead compounds with greater ligand efficiency. FBDD thus allows a bottom-up approach through which a wider space can be investigated, which enables the development of higher affinity lead compounds with high specificity.